Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation AHA 2024

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Presenter: Chisato Izumi

November 17, 2024

Presentation NY Valves 2024

Direct Oral Anticoagulants Versus Vitamin K Antagonists After TAVR

Presenter: Agam Bansal

June 06, 2024

Presentation TCT 2022

TCT 362: Direct-acting Oral Anticoagulants versus Vitamin K Antagonists in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis

Presenter: Khawaja Akhtar

September 19, 2022

Presentation TCT 2022

TCT 359: Continued Oral Anticoagulation With Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists in Transcatheter Aortic Valve Implantation

Presenter: Norman Mangner

September 19, 2022

Presentation TCT 2022

TCT 381: Vitamin K Antagonists, Direct Oral Anticoagulants, or Left Atrial Appendage Closure for Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Presenter: Davide Cao

September 18, 2022

Presentation TVT 2022

Real World Outcomes of Left Atrial Appendage Occlusion compared to Novel Oral Anticoagulants - A multicenter electronic health record analysis

Presenter: Arka Chatterjee

June 10, 2022

Presentation TCT 2020

TCT 449: Direct Oral Anticoagulants vs. Warfarin Following Left Atrial Appendage Occlusion: A Study-Level Meta-Analysis

Presenter: Aravdeep Jhand

October 14, 2020

Presentation TCT 2018

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Presenter: James B. Hermiller Jr, David Hildick-Smith, Martin W. Bergmann

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Presenter: James B. Hermiller Jr, David Hildick-Smith, David R. Holmes Jr.

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Presentation The Structural Heart Disease Summit 2018

Updated Watchman Results in Anticoagulant Indicated and Contraindicated Patients: Randomized Trials and Registries

Presenter: William A. Gray, Gregg W. Stone, Matthew J. Price

June 22, 2018

Presentation TCT 2017

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Samir R. Kapadia, David J. Moliterno

November 01, 2017

Presentation

CLOSE: Closure of PFO, Oral Anticoagulants, or Antiplatelet Therapy to Prevent Stroke Recurrence

May 24, 2017

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Advertisement

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Direct Oral Anticoagulants Versus Vitamin K Antagonists After TAVR

TCT 362: Direct-acting Oral Anticoagulants versus Vitamin K Antagonists in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis

TCT 359: Continued Oral Anticoagulation With Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists in Transcatheter Aortic Valve Implantation

TCT 381: Vitamin K Antagonists, Direct Oral Anticoagulants, or Left Atrial Appendage Closure for Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Real World Outcomes of Left Atrial Appendage Occlusion compared to Novel Oral Anticoagulants - A multicenter electronic health record analysis

TCT 449: Direct Oral Anticoagulants vs. Warfarin Following Left Atrial Appendage Occlusion: A Study-Level Meta-Analysis

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Updated Watchman Results in Anticoagulant Indicated and Contraindicated Patients: Randomized Trials and Registries

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

CLOSE: Closure of PFO, Oral Anticoagulants, or Antiplatelet Therapy to Prevent Stroke Recurrence

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content